The FTC v POM: What happens next?
Exactly what kind of evidence is needed to support structure/function or disease risk reduction claims on foods and supplements? And did POM Wonderful cross the line with ads promoting its pomegranate juice for reducing the risk of prostate cancer and cardio disease?
This month we learned that clearer answers to these questions will emerge on August 23 when five FTC Commissioners will hear oral arguments from POM and the Federal Trade Commission (FTC), which have both appealed a recent initial decision from administrative law judge Michael Chappell on a false advertising case brought by the FTC against POM in 2010.
Click here for details.